CVS Stock Recent News
CVS LATEST HEADLINES
When you're building a diversified portfolio for long-term wealth, it sometimes can be easy to ignore dividend stocks in favor of high-powered growth names in the tech sector. After all, companies like Nvidia, Palantir Technologies, and Microsoft are some of the biggest players out there, and investors flock to them to lock in market-beating gains.
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
CVS is focusing heavily on technology-led care after posting solid Q2 earnings. “We are building momentum as we navigate what continues to be a dynamic and evolving environment,” Chief Executive David Joyner told analysts on an earnings call Thursday (July 31), crediting the company's “diversified business” for offsetting swings in medical costs.
CVS Health Corp (NYSE:CVS) reported better-than-expected financial results for the second quarter, driven by robust growth across its retail pharmacy, insurance (Aetna), and health services segments. Total revenue was up 8.4% at $98.9 billion, above Wall Street estimates of $94.7 billion.
Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.
CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.
Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The company boosts its full-year guidance range for adjusted earnings on the heels of a strong second quarter.
Shares of CVS Health (CVS) jumped in premarket trading Thursday after the health care giant posted better-than-expected second-quarter results and lifted its full-year adjusted profit forecast.